The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.
AnaBios, a US-based preclinical contract research organization, has acquired Cell Systems, a US-based human primary cell and cell culture media company, in a deal that will bolster AnaBios’ human tissue and cells portfolio. Financial terms of the transaction were not disclosed.
The acquisition will help scientists expedite drug discovery and further understanding of cell biology through access to an expansive array of biologically relevant tools, AnaBios announced in an April 4, 2023 press release.
Cell Systems’ offering includes a variety of human primary cells, including endothelial cells from the brain, liver, kidney, eye, and lung. The company’s liver sinusoidal endothelial cells were used in a recent pivotal study of a novel liver-chip model that was said to have rigorously validated the use of the primary cells for microfluidics application in accordance with industry standards set by the International Consortium for Innovation and Quality in Pharmaceutical Development, according to the press release.
AnaBios’ advanced technologies provide human tissue samples, cells, and services for the pharmaceutical industry and academic laboratories globally. Human primary cells and tissues are important for providing clinically relevant data to increase the success rate of drug development.
“Cell Systems has decades of experience supplying our … human primary cells to pharma/biotech companies and universities around the world that enable translational research using 2D and 3D models, microfluidic devices, and in organ-chip technology. Our primary cells have been instrumental in research of the blood-brain-barrier, liver biology, kidney function, respiratory biology, and much more,” said Jesse Damm, CEO of Cell Systems, in the press release.
“AnaBios is extremely excited to provide Cell Systems’ primary cells to researchers globally and further enhance the landscape of translational research,” said Andre Ghetti, CEO of AnaBios, in the release. “By maximizing the synergies between our offerings and expertise and Cell System’s human primary cells and media, we will provide enhanced translational tools and reagents to academic, pharmaceutical, and biotech researchers and optimize their research programs through enhanced human insights.”
Source: AnaBios
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.